From Rybelsus to the Wegovy Pill: What Pharmacists Need to Know About the Next Generation of Oral Semaglutide

When the FDA approved semaglutide tablets (Rybelsus; Novo Nordisk) in 2019, it marked a breakthrough: the first oral glucagon-like peptide-1 (GLP-1) receptor agonist available in the United States for adults with type 2 diabetes (T2D). Now, that landscape has transformed significantly.¹

In December 2024, the FDA approved a next-generation oral semaglutide formulation (R2) at doses of 1.5 mg, 4 mg, and 9 mg, offering improved bioavailability. A year later, in December 2025, the FDA approved once-daily oral semaglutide 25 mg as the Wegovy pill (Novo Nordisk), the first oral GLP-1 receptor agonist indicated for chronic weight management. As of May 4, 2026, Novo Nordisk launched the R2 formulation nationwide under the Ozempic brand name, effectively phasing out Rybelsus in the US.^1,2,3

With shifting names, dosages, and indications, it is pivotal for pharmacists to educate themselves on what the current landscape for oral GLP-1 medication looks like—and what they need to know about efficacy and safety for patients.

A Reformulation, Not a New Drug

Rybelsus (R1 formulation) relies on co-formulation with salcaprozate sodium (SNAC), an absorption enhancer that locally raises gastric pH to protect semaglutide from enzymatic degradation and facilitates transcellular absorption through the stomach wall. Despite this engineering, oral bioavailability remains below 1%, making strict adherence to administration conditions essential.^4,5

The R2 formulation achieves approximately 25% greater semaglutide exposure than R1 through improvements in excipient composition. This enhanced bioavailability allows lower absolute doses to deliver equivalent therapeutic exposure: 1.5 mg (R2) is bioequivalent to 3 mg (R1); 4 mg (R2) to 7 mg (R1); and 9 mg (R2) to 14 mg (R1). Pharmacists must counsel patients that the dose number on their label has changed, but the therapy has not. The products are not milligram-for-milligram interchangeable, and patients should not switch formulations without provider guidance.^6,7

Expanded Indications: CV Outcomes and Weight Management

In October 2025, oral semaglutide received FDA approval for cardiovascular (CV) risk reduction in adults with T2D at high CV risk, supported by the SOUL trial, a double-blind, placebo-controlled outcomes trial of 9650 patients. SOUL demonstrated a significantly lower risk of major adverse cardiovascular events (MACE) with oral semaglutide versus placebo, with benefits consistent across subgroups regardless of SGLT2 inhibitor use.^8,9

The Wegovy pill's December 2025 approval was supported by OASIS 4, a 64-week phase 3 trial of 307 adults with obesity or overweight without diabetes. Patients receiving once-daily oral semaglutide 25 mg achieved a mean body weight reduction of 13.6% from baseline versus 2.2% with placebo; among those who remained on treatment, mean weight loss reached 16.6%, with approximately 1 in 3 achieving 20% or greater weight loss. Novo Nordisk has noted comparable efficacy between the Wegovy pill and injectable Wegovy in indirect treatment comparisons.^10,11

Adverse Effects: What Has—and Has Not—Changed

The adverse effect profile across all oral semaglutide formulations remains characteristic of the GLP-1 receptor agonist class: nausea, diarrhea, vomiting, and constipation are most common, tend to be dose-dependent, and typically attenuate over time. Oral semaglutide's low, variable bioavailability may contribute to a modestly higher gastrointestinal (GI) burden compared with subcutaneous formulations. All semaglutide products carry a boxed warning for risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pharmacists should also be aware that the FDA recently added delayed gastric emptying to the semaglutide label as a labeled adverse event, with implications for perioperative management.^12,13

The Pharmacist's Role in Counseling and Transition

Pharmacists are uniquely positioned to prevent errors and support patients through this transition. Several counseling priorities stand out. First, administration instructions remain non-negotiable: all oral semaglutide formulations must be taken first thing in the morning, on an empty stomach, with no more than 4 ounces of plain water, and at least 30 minutes before food, beverages, or other oral medications. Second, patients transitioning from Rybelsus to the Ozempic tablet should be reassured proactively that a lower dose number does not mean a weaker medication. Third, for patients initiating the Wegovy pill, pharmacists should set realistic expectations; meaningful weight loss unfolds over months, and GI symptoms during dose escalation are normal and manageable.^4,7,14

Strategies for mitigating GI adverse effects include eating smaller, lower-fat meals; avoiding recumbency after eating; and maintaining adequate hydration. Patients taking concomitant insulin or sulfonylureas should be counseled about hypoglycemia risk and the potential need for dose adjustments. Breastfeeding is not recommended during oral semaglutide therapy due to SNAC accumulation in human milk, and patients of reproductive potential should receive explicit guidance, as semaglutide is contraindicated in pregnancy.^5,12

The shift from Rybelsus to the Ozempic tablet and Wegovy pill represents a meaningful clinical evolution—not a cosmetic rebrand. With improved bioavailability, expanded indications for CV risk reduction and weight management, and a patient population actively seeking oral GLP-1 options, pharmacists who are fluent in these distinctions will be essential partners in ensuring safe, effective, and well-counseled transitions.

REFERENCES

1. Rybelsus (semaglutide) tablets [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2025. Accessed May 26, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf

2. Valletti D. FDA approves first oral GLP-1 for weight management. Pharmacy Times. Published December 23, 2025. Accessed May 26, 2026. https://www.pharmacytimes.com/view/fda-approves-first-oral-glp-1-for-weight-management

3. Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US. News release. Novo Nordisk. PR Newswire. Released May 1, 2026. Accessed May 26, 2026. https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html

4. Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of oral semaglutide in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781-791. doi:10.1007/s40262-018-0728-4

5. Kane MP, Triplitt CL, Solis-Herrera CD. Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. Am J Health Syst Pharm. 2021;78(7):556-567. doi:10.1093/ajhp/zxaa413

6. Nielsen MS, Brøndsted L, Kankam M, et al. A bioequivalence study of two formulations of oral semaglutide in healthy participants. Diabetes Ther. 2025;16(2):269-287. doi:10.1007/s13300-024-01674-8

7. Sista S, Absar M, Penzenstadler J, Earp J, Khurana M. Clinical pharmacology review: oral semaglutide formulation R2. FDA. Submitted March 20, 2019. Accessed May 26, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000ClinPharmR.pdf

8. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006

9. Marx N, Deanfield JE, Mann JFE, et al. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation. 2025;151(23):1639-1650. doi:10.1161/CIRCULATIONAHA.125.074545

10. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969

11. Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors. News release. Novo Nordisk. Released November 5, 2025. Accessed May 26, 2026. https://www.prnewswire.com/news-releases/novo-nordisk-presents-four-new-analyses-on-oral-semaglutide-25-mg-wegovy-in-a-pill-at-obesityweek-2025-including-demonstrated-reductions-in-cardiovascular-risk-factors-302605329.html

12. Gallagher A. FDA adds delayed gastric emptying as adverse event on semaglutide label. Published November 14, 2024. Accessed May 26, 2026. https://www.pharmacytimes.com/view/fda-adds-delayed-gastric-emptying-as-adverse-event-on-semaglutide-label

13. Mechanism of action of RYBELSUS (semaglutide), the only FDA-approved semaglutide in a pill for adults with T2D. Novo Medlink. Accessed May 26, 2026. https://www.novomedlink.com/diabetes/products/treatments/rybelsus/about/mechanism-of-action.html

14. Alhazmi A, le Roux CW. Do no harm: managing nausea and vomiting in GLP-1–based obesity therapies. Front Endocrinol. 2026;17:1788698. doi:10.3389/fendo.2026.1788698